𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts

✍ Scribed by Cao, P; Maira, S-M; García-Echeverría, C; Hedley, D W

Book ID
109999999
Publisher
Nature Publishing Group
Year
2009
Tongue
English
Weight
487 KB
Volume
100
Category
Article
ISSN
0007-0920

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The efficacy of a novel, dual PI3K/mTOR
The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer
✍ Niranjan Awasthi; Peter L. Yen; Margaret A. Schwarz; Roderich E. Schwarz 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 419 KB

## Abstract Gemcitabine has limited clinical benefits for pancreatic ductal adenocarcinoma (PDAC). The phosphatidylinositol‐3‐kinase (PI3K)/AKT and mammalian target of rapamycin (mTOR) signaling pathways are frequently dysregulated in PDAC. We investigated the effects of NVP‐BEZ235, a novel dual PI